Pulmonary Fibrosis-on-a-Chip Model

Pulmonary fibrosis is a late-stage manifestation of a variety of lung diseases that involve the proliferation of fibroblasts and the accumulation of a significant amount of extracellular matrix. This process is accompanied by inflammatory injury and destruction of tissue structure. The integrated biomimetic array chip (iBAC) M1 is employed to construct a human-derived pulmonary fibrosis model using the patient's primary tissue. This model offers high bionics and high throughput advantages, which can aid in the development of new anti-fibrosis drugs.

• Pulmonary Fibrosis: Principles of Microphenotyping on a Chip
Collagen shrinkage combined with AI image recognition on the IBAC S1 chip is a new index for anti-fibrotic drug evaluation, with the advantages of low cost and high sensitivity.
• Anti-pulmonary fibrosis drug evaluation
The microphenotypes of pirfenidone, entinostat, and talabox mesylate showed antifibrotic efficacy starting at concentrations of 1.5mM, 0.625μM, and 160μM, which were consistent with the effective concentrations reported in the literature. The three drugs have different anti-fibrotic pharmacodynamic mechanisms, but share universal microscopic phenotype indicators that are used for evaluating their effectiveness as anti-fibrotic drugs.

Please contact us at for specific academic pricing.